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Inﬂammatory breast cancer (IBC) is a clinico-pathological entity, which has speciﬁc features of inﬂam-
mation and pathological evidence of cancer, most often involving dermal lymphatics. This review looks
at IBC from the pathologists point of view. The diagnostic criteria and differential diagnosis are sum-
marized ﬁrst. The staging implications are described next. Despite the overall poor prognosis of IBC, it is
heterogeneous in terms of most prognostic and predictive factors (such as histological type, grade, re-
ceptor status, intrinsic subtype, inﬂammatory inﬁltrate). It seems that some molecular features (genes
expressed) are unique to IBC, and this may help to identify them as IBC at the molecular level. The key
carcinogenetic pathways activated in IBC, the inﬂammatory pathways present in the disease as well as
the relation of IBC to cancer stem cells are also brieﬂy covered. Due to the relative rarity of IBC, preclinical
trials are very important in the study of this entity, and models with stromal and microenvironmental
elements are expected to outperform the traditional models without these features, as the microenvi-
ronment seems to be a key component of IBC.
© 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical
Oncology. All rights reserved.Inﬂammatory breast cancer (IBC) is a special manifestation of
breast cancer that is associated with extremely bad prognosis. After
dealing with diagnostic criteria and recognition of the disease and
its staging implications, the molecular background of this special
presentation will be explored in this review.Diagnostic considerations
As the name implies, IBC combines the clinical presentation of
breast carcinoma with signs of locoregional inﬂammation, and
should therefore be differentiated from several forms of non-
cancerous mastitis.
Mastitis in its acute (sudden onset and/or short duration) form is
characterized by the symptoms described by Celsus and taught to
generations of physicians over the centuries: rubor (redness due to
active hyperaemia), calor (raised local temperature over the
inﬂamed area), tumor (swelling and/or mass formation due toing Hospital, Department of
on for Cancer Surgery, and the Eur
ser (n/a) at HUNGARY - Szeged Uni
nly. No other uses without permission.oedema) and dolor (pain). All these cardinal signs are assessed and
best appreciated clinically, while only two of them may have his-
tologic correlates: dilated capillaries can reﬂect the redness, but are
not always seen, as active hyperaemia is a functional change which
may disappear ex vivo. Dilated capillaries seen in biopsies from IBC
are generally of the lymphatic type, and can be highlighted with
lymphatic endothelium speciﬁc markers, such as D2-40, podopla-
nin and LYVE-1, and may contain tumour emboli. Substantial
oedema leading to the peau d'orange appearance can be appreci-
ated in tissue biopsies, but is not easy to discriminate from tissue
processing artefacts, myxoid degenerative changes or simply loose
connective tissue. It must also be noted that redness cannot be
evaluated in people with pigmented skin, as the high melanin
content of the skin may suppress the colour of capillary dilatation
[1], although some changes in tint/tone can often be appreciated
[2]. In contrast, neutrophils, the classic histologic feature of acute
inﬂammations, are lacking in IBC.
Acute mastitis is generally caused by infectious agents, most
often pyogenic bacteria, especially Staphylococcus aureus, entering
the breast parenchyma through small skin disruptions, cracks
caused by breastfeeding, eczema or mechanical irritation.opean Society of Surgical Oncology. All rights reserved.
versity from ClinicalKey.com by Elsevier on January 16, 2019.
 Copyright ©2019. Elsevier Inc. All rights reserved.
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other forms may lead to a more diffuse cellulitis as seen with
Streptococcal infections. Timely systemic administration of antibi-
otics may alter the clinical course of acute mastitis and often pre-
vent abscess formation [3]. Chronic forms of mastitis (with longer
duration and less abrupt start) also exist and have symptoms
overlapping with acute mastitis; their aetiology includes infectious
(e.g. tuberculous mastitis, cystic neutrophilic granulomatous
mastitis) and non-infectious causes (e.g. periductal/plasma cell
mastitis, idiopathic granulomatous mastitis, autoimmune mastitis
(e.g diabetic mastopathy)).
IBC by deﬁnition presents in the form of acute mastitis; the
onset is abrupt. Experts have agreed that symptoms of inﬂamma-
tion should be present for no more than 6 months to allow for the
diagnosis of IBC [4], but often the history is much shorter, and dates
back to only a few weeks [5]. By deﬁnition, the erythema must
involve at least one third of the breast [1]. On the basis of the
previous considerations, it is not surprising that the inﬂammatory
nature is diagnosed clinically (swelling, peau d'orange, enlarge-
ment, erythema, pain, which sometimes involves the axilla too),
whereas the neoplastic nature is diagnosed by microscopy and
often preceded by imaging. Most forms of mastitis (the common
ones) respond to antibiotics, but those not responding to an
adequate course of such treatment should undergo further in-
vestigations as to alternative causes of the inﬂammation: patho-
gens (including parasites) unresponsive to the given antibiotics
[6e9], non-infectious causes mimicking cancer [10,11], or cancer
itself. To render the diagnosis of IBC, microscopic veriﬁcation of
tumour emboli in the lymphatics of the skin and preferably the
underlying invasive carcinoma itself is mandatory.
Many IBC cases lack a palpable lump on physical examination; in
fact, this is the typical presentation. As concerns imaging, ultrasound
(US) often outperforms mammography, and often highlights axillary
lymph node involvement. Magnetic resonance imaging (MRI) is
somewhat more sensitive than US. The most common ﬁndings on
MRI are multiple, small, heterogeneously enhancing nodules along
with diffuse skin thickening [12,13]. Whenever a mass lesion is
visualized, a core needle biopsy should establish the diagnosis of an
underlying cancer. Fine-needle aspiration may also have a role in
establishing the diagnosis of IBC [2]. In a small series of 5 patients, the
authors used a “tangential” technique to aspirate the superﬁcial
oedematous dermis, and have seen malignant cells in 4/5 cases of
suspected IBC after aspirating all four quadrants; this diagnostic yield
was greater than that of core needle biopsies of the skin [2]. If no
lump can be visualized by US, or if core needle biopsy fails, it is
common practice in our department to introduce a free needle into
the dermis of patients with suspected IBC and let the pressure of the
oedema bring out some ﬂuid and accompanying cells which can be
smeared for staining and microscopy; this approach has also led to
the identiﬁcation of IBC. Proving malignancy from regional axillary
lymph nodes may also be sufﬁcient in the context of IBC. Core needle
biopsy may be preferred to ﬁne needle aspirates in these cases,
because it renders tissue samples better suited for histologic,
immunohistochemical andmolecular characterization of the tumour.
It is advised to take several cores and embed them separately to
allow prognostic and predictive marker (oestrogen receptor (ER),
progesterone receptor (PR), human epidermal growth factor
receptor-2 (HER2)) studies before primary systemic treatment and
even further studies after surgery, if complete response occurs. If
possible, tumour tissue should also be taken for biobanking.
Whenever the diagnosis of cancer is made in the setting of a
sufﬁciently large (at least one third of the breast) inﬂammatory
presentation, the diagnosis of IBC can be made with conﬁdence,
although secondary cancers which are rare in the breast have also
been reported to imitate IBC [14e17].Downloaded for Anonymous User (n/a) at HUNGARY - Szeged Univers
For personal use only. No other uses without permission. CopIt has long been debated whether or not dermal lymphatic in-
vasion is a sine qua non for the diagnosis of IBC. Swelling is mainly
due to lymphedema, i.e. to the obstruction of the lymph ﬂow either
due to lymphatic emboli and/or massive nodal obliteration.
Although the ﬁnding of dermal lymphatic tumour emboli is com-
mon in IBC (up to 75% have proven lymphatic invasion in the
dermis) and this ﬁnding strengthens the diagnosis, there is agree-
ment that this is not required to establish the diagnosis of IBC [1]
for which the clinical presentation is overriding. Punch biopsies
are suitable to sample the dermis and discover lymphatic tumour
emboli in many patients [18]. A minimum of two punch biopsies
(2e8 mm in diameter) has been advised from the area demon-
strating the most prominent discoloration [4] or peau d'orange sign
[19]. Alternately, small incisional biopsies may lead to the same
result. These samples also demonstrate skin thickening [18].
In summary, neither a breast cancer without the characteristic
signs of IBC (rapid onset of erythema, enlargement, oedemawith or
without the peau d'orange sign, and/or warmth, with or without a
palpable tumour, and involvement of at least a third of the breast)
nor the listed symptoms of inﬂammation without a proven breast
cancer qualify for IBC, the two ought to be together. Therefore, IBC is
a clinico-pathological diagnosis [5,20e24] which requires a multi-
disciplinary approach for diagnosis [25].
Staging implications, prognostic and predictive factors
IBC is considered to represent an advanced stage. It is coded as
T4d (a category reserved for IBC) according to the TNM classiﬁca-
tion, which, however, does not make any distinction between other
T4 categories and the T4d as determinant of stage. As a potential
source of confusion, the T4b category, i.e. a cancer with extension to
the skin deﬁned as ulceration and/or satellite dermal nodules and/
or oedema, includes the peau d'orange sign if it does not meet the
criteria for IBC. All T4 cancers belong to (anatomic) stage IIIB, unless
nodal involvement reaches N3 (stage IIIC) or distant metastasis is
present (stage IV) [23,26]. The American Joint Committee on Cancer
(AJCC) has also introduced prognostic stages into the last edition of
the staging manual [23]. According to this, a T4N0-3M0, grade 1
tumour with a HER2 negative, but ER and PR positive status would
be of stage IIIA, i.e. would be downstaged compared to its anatomic
stage deﬁned by the T, N and M categories alone. Nodal metastases
are very common in IBC. An analysis of more than 750 cases from
the Survival Epidemiology and End-Results database suggested that
only 20% of the cases were node negative, and that nodal status was
of prognostic impact even in IBC [27]. More than one third of the
cases have 10 or more nodes involved, and are therefore in category
pN3 [28].
Most locally advanced breast cancer (LABC) cases have skin
involvement (pT4b or pT4c), which include ulceration, satellite
cutaneous nodules or the peau d'orange sign, and/or histologic
inﬁltration of the dermal lymphatics by tumour emboli. Localised
inﬂammatory signs may also develop either as a result of ulceration
and infection or as a result of tumour necrosis and/or stasis.
Although peritumoural lymphatic invasion is commonly present,
diffuse skin thickening and dermal lymphatic involvement is not a
feature of LABC, which is clinically distinguished from IBC on the
basis of the absent or limited inﬂammatory signs [18]. In parallel,
ulceration and cutaneous nodules are not features of IBC [1]. In the
rare case, when all the clinical features of IBC are present, and
carcinoma is diagnosed as the disease behind the inﬂammatory
signs, but the skin area involved is smaller than one third of the
breast, it was suggested to classify the disease as T4b or T4c in the
7th edition of the AJCC Cancer staging manual [22], a suggestion
that is missing from the 8th edition in use from January 2018 for
unknown reasons [24]. However, as involvement of at least oneity from ClinicalKey.com by Elsevier on January 16, 2019.
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G. Cserni et al. / European Journal of Surgical Oncology 44 (2018) 1128e11341130third of the breast is part of the deﬁnition of IBC, such cases should
not be labelled as IBC for staging, even if one is tempted to treat
them according to this diagnosis.
Although stage is not inﬂuenced by the presence of inﬂamma-
tory signs, IBC is generally deﬁned separately in the staging books.
Clinical symptoms deﬁning the entity have been differently worded
in different editions. There are consistent parts of the deﬁnition, but
the wording has also slightly changed over the years, at least as
concerns the AJCC staging books (Table 1) [20e23,26,29,30]. The
UICC TNM books have also a note saying that whenever the skin
biopsy is negative for cancer, and there is no “localized measurable
primary” carcinoma detected, the pathological staging category
should be pTx for a cT4d tumour [29,30]. This is difﬁcult to inter-
pret, in the light of the pathological pT categories and clinical cT/T
categories being identically deﬁned, a measurable tumour size not
being part of the deﬁnition of the T4d category, but the proof of
carcinoma being essential for the diagnosis of IBC, i.e. T4d.
These staging rules suggest that IBC is perceived as an advanced
stage disease which, on the base of its clinical presentation, should
however be distinguished from LABCs having a long history and a
slower development. There are data to suggest that IBC differs from
other advanced stage breast cancers in several aspects.
According to a recent analysis of nearly 600 IBC cases from the
National Cancer Database, IBC can represent either ER and/or PR
positive tumours with a HER2 negative (39%) or positive (16.5%)
status, or HER2 positive, ER and PR negative tumours (18.9%) or
triple negative carcinomas (25.6%) [31]. Compared to non-IBC, the
more aggressive, ER negative phenotypes thereby not surprisingly
dominate [32]. HER2 positive cases had the best survival, probably
due to effective anti-HER2 targeted treatments [31,33,34], whereas
hormone receptor positive tumours had worse outcome [31,35],
probably due to their moderate response to chemotherapy. Even
with aggressive treatments, patients with triple negative IBC have
the worst survival of all [34]. Patients with triple negative cancers
presenting as IBC have worse survival than those with non-
inﬂammatory presentation [36], indicating that they respond less
well to chemotherapy than their non-IBC counterparts. Some au-
thors have not found survival differences between IBCs of different
phenotypes classiﬁed on the basis of ER, PR and HER2 status [37].
As patients with IBC are often relatively young and the diagnosis
of breast cancer in the young is part of the indication for suscep-
tibility gene testing, the mutational status of the BRCA1 and BRCA2
genes, themost common susceptibility genes for breast cancer, may
be of special interest. A large series from the MD Anderson Cancer
Center including 105 IBC and 1684 non-IBC with BRCA genetic
testing results suggests that there are no differences between the
two presentations, i.e. IBC is not associated with BRCA1 or BRCA2
pathogenic variants [38].
As implied by the extreme aggressiveness of IBC, it is not sur-
prising that the majority of patients have histological grade 3 tu-
mours; although a small minority do have grade 1 carcinomas
[28,39]. Most IBC are carcinomas of no special type, but lobular
carcinomas and other special type carcinomas have also been re-
ported as IBC in about 5% and 4%, respectively [40]. Although
invasive micropapillary carcinoma is known to often be accompa-
nied by extensive lymphovascular invasion, this subtype does not
seem to be overrepresented in IBC.
Lymphovascular invasion is a prerequisite for lymph node me-
tastases to develop. Therefore, practically all patients with regional
lymph nodemetastasis should have (had) lymphatic tumour emboli.
However, this feature is not always seen in specimens of node-
positive primary breast carcinomas. The discrepancy may be
explained by a spatial and temporal distribution of the emboli: they
might have been present at the time of histological assessment, but
at areas different from those sampled; or alternately, they mightDownloaded for Anonymous User (n/a) at HUNGARY - Szeged University from ClinicalKey.com by Elsevier on January 16, 2019.
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when lymphovascular invasion is identiﬁed, it may reﬂect its
massive presence (when sampling any area would reveal the same
presence) or a chance ﬁnding (whenmost other areaswould lack the
feature). Most IBC cases have extensive dermal lymphatic emboli,
but some tumours without inﬂammatory signs do have extensive
peritumoral lymphatic invasion, and the latter have still better dis-
ease free and overall survival [28], suggesting that dermal lymphatic
invasion is not the only difference in IBC and non-IBC. Both increased
lymphangiogenesis and angiogenesis have been documented in IBC,
giving the increased vascular invasion a molecular background [41].
Colpaert et al. also demonstrated an increased level of angiogenesis
in IBC versus non-IBC samples and suggested that increased angio-
genesis in the IBC tumours was, for the most part, not stimulated by
hypoxia but was due to a vasculogenic phenotype [42]. An IBC
xenograft model,WIBC-9, has been extensively studied and revealed
invasive ductal carcinoma pattern with a hypervascular structure of
solid nests and marked lymphatic permeation in the overlying
dermis [43,44]. WIBC-9 exhibited aneuploidy, HER2 gene ampliﬁ-
cation, and absence of hormonal receptors, which is consistent with
IBC. In the central part of the solid nests, vasculogenic mimicry was
observed, with an absence of endothelial cells. Vasculogenic mim-
icry was described in many aggressive tumours as blood vessels
formed by tumour cells instead of endothelial cells [45,46]. Molec-
ular analysis indicated the vascular phenotype of this xenograft,
with expression of vascular markers such as Flt-1 and Tie-2, even in
the areas that displayed vascular mimicry. This model was used to
describe the vasculogenic phenotype of IBC, and suggested a
connection between vasculogenic mimicry and angiogenesis [47].
Vasculogenic mimicry can also explain the metastatic route of IBC,
and why IBC is so aggressive clinically.
Primary human IBC derived cell-line and xenograft derived-
models have helped to clarify some aspects of the formation of
dermal lymphatic emboli. Overexpression of the transmembrane
adhesion protein E-cadherin was one of the factors identiﬁed as
being responsible for the formation of such emboli; the E-cadherin
effect could be reduced by downregulating the E-cadherin-catenin
axis [48]. Another molecule with conﬁrmed importance is MUC1,
which is involved in tumour emboli binding to lymphovascular
endothelial cells. The markedly decreased sialyl-Lewis x/a (sLex/a)
carbohydrate ligand-binding epitopes on overexpressed MUC1
participate in the passive dissemination of emboli [49,50].
Schneider et al. also demonstrated that the unique pathogenic
properties of IBC result in part from overexpression of the trans-
lation initiation factor eIF4G1. This overexpression leads to a spe-
ciﬁc increase in the translation of internal ribosomal entry site
(IRES) containing mRNAs. Speciﬁcally, two such mRNAs, p120 cat-
enin and VEGF, encode key proteins involved in the pathogenesis of
IBC. The p120 catenin protein causes retention of E-cadherin at the
cell surface and VEGF produces angiogenic effects and resistance to
hypoxia. Silencing of eIF4G1 caused marked reduction in p120
catenin protein levels and cell surface associated E-cadherin
expression in SUM149 cell-line cells. Ectopic overexpression of
p120 catenin in eIF4G1 silenced cells was able to restore invasion,
E-cadherin cell surface localization, tumour growth and hence
ability to generate IBC mammospheres to the levels observed in
controls [51].
IBC and gene-expression proﬁles
In current clinical practice, commercially available gene
expression proﬁle (GEP) based diagnostic tests are deemed useful
to tailor individual patients' treatment, i.e. to identify patients who
would require aggressive systemic treatment and those whowould
not beneﬁt from such an approach, especially in cases whereDownloaded for Anonymous User (n/a) at HUNGARY - Szeged Univers
For personal use only. No other uses without permission. Coptraditional prognostic factors are borderline. Therefore, the indi-
cation to use gene-expression proﬁles in IBC is missing at the
clinical level, which may explain the relative scarcity of data
derived from GEPs.
The largest series assessing the composition of IBCs according to
intrinsic subtypes on the basis of GEP comes from the World IBC
Consortium [40]. After assessing 137 IBCs with the PAM-50 algo-
rithm complemented with the additional identiﬁcation of the
claudin-low subtype, it became clear that all subtypes are repre-
sented: 26 (19%) showed luminal A and luminal B characteristics
each, whereas 30 (22%), 24 (17%), 23 (17%) and 8 (6%) were of the
HER2 enriched, basal-like, claudin-low and normal breast like
types, respectively [40].
When the intrinsic subtypes are approached by immunohisto-
chemistry (IHC), the match between the gene-expression derived
subtypes (luminal A and B, HER-2 enriched, basal-like) and the
differently deﬁned IHC based groups (luminal A-like, luminal B-
like, HER2(ER-negative) and triple negative) is less than perfect.
Kertmen et al. suggested that IBC belonged to luminal A-like car-
cinomas as often as 35% (27/78) in a Turkish population, but their
deﬁnition for luminal A was not provided, and may not have been
restrictive enough [37]. To support this latter explanation (i.e.
deﬁnition not restrictive enough), only 10% (7/67) of IBC in a Chi-
nese population were classiﬁed as luminal A-like with the 2011 St
Gallen IHC deﬁnitions (ER-positive, HER2-negative, Ki67<14%
labelling) [52].
IBC is therefore a clinicopathologic entity that is not uniform in
histologic type, grade, IHC phenotype, or GEP based intrinsic sub-
types. The question therefore arises whether anything else distin-
guishes IBC from non-IBC. Possible approaches include the search
of such distinguishing features in the tumours or the host (e.g. the
immune response to cancer), methylation patterns or changes in
expression of microRNAs.
When compared to non-IBCs, IBCs showed higher activation of 8
molecular pathways (CTNB, HER2, MYC, RAS, IFNa, IFNc, TNFa and
VEGF) along with lower activation of 4 pathways (ER, PR, p53 and
TGFb), whereas the remaining of the assessed activity pathways
(AKT, E2F1, EGFR, PI3K, SRC, STAT3 and p63) showed no statistical
differences [40]. Downregulation of the TGFb pathway has also
been related to the propensity of IBC to spread through the lym-
phatics [40]. A smaller series has pointed to relatively common
alterations in other pathways, such as alterations in HER3 often
coexisting with HER2 alterations [53]. A set of 78 transcription
factors also showed difference in activation between IBCs and non-
IBCs, including the hyperactivation of RELA (a nuclear factor kappa
B e NFkB-component) in IBC [40]. This is in keeping with earlier
and recent studies suggesting a role for NFkB-related genes in IBC
[54,55]. However, differences observed between IBC and non-IBC
are not all related to the inﬂammatory nature of IBC. When look-
ing at speciﬁc genes that are uniquely expressed in IBC as compared
to non-IBC, a set of 79 genes were identiﬁed as being uniquely
speciﬁc for IBC, and their expression may be of help in the molec-
ular deﬁnition of IBC and used as an IBC GEP classiﬁer [40].
Inﬂammation in IBC
Carcinogenesis, cancer growth and metastasis are closely linked
to tumour microenvironment. The intrinsic link between inﬂam-
mation and cancer is both an old and a very contemporary story.
More than a century ago, Rudolf Virchow and colleagues hypoth-
esized for the ﬁrst time that inﬂammation was associated with
tumours [56]. Nowadays it would be difﬁcult to deal with cancer
and skip the inﬂammatory process.
Modulation of inﬂammation and immunity is implicated in
tumour growth and survival, but is also becoming a successfulity from ClinicalKey.com by Elsevier on January 16, 2019.
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using immune checkpoint inhibitors in lung cancer and mela-
noma [57]. In breast cancer, too, the immune environment plays a
role in aggressive molecular types, like basal-like and triple
negative carcinomas [58]. The immune component is fully
implicated in tumoural response to neoadjuvant chemotherapy
[59]. Clinical trials to restore host immune response, like the ones
targeting the PD1/PDL1 or the CTLA4 axis are currently running.
Recent reports suggest that targeting protein glycosylationwith a
monoclonal antibody is a potential strategy to enhance immune
checkpoint therapy in triple negative breast cancers [60]. Path-
ological guidelines to quantify tumour inﬁltrating lymphocytes
have been published and updated, as this parameter is currently
evaluated as a biomarker for including breast cancer patients in
clinical trials [61,62].
As to the immune inﬁltrate in IBC, tumours seem to be relatively
heterogeneous. A signiﬁcant minority of IBCs (5/12; 95% conﬁdence
interval: 19e68%) displayed high rates of tumour inﬁltrating lym-
phocytes (TILs) according to the authors deﬁnition (>5% intra-
tumoural area), which is different from the International TILs
Working Group recommendation mandating at least 50% stromal
TILs for a lymphocyte predominant breast carcinoma [61,62]. In
keeping with results described in breast cancer in general, a low
percentage of these lymphocytes belong to the regulatory
FOX3P þ T-cells, which are thought to represent a tumour pro-
moting effect, and the majority are CD8þ cytotoxic cells [53].
However, other IBC lack this degree of lymphocytic inﬁltration,
leading to the conclusion that TILs are not responsible for the IBC
phenotype.
Similarly to lymphocytes, according to the immune-editing
theory of cancer, tumour associated macrophages (TAMs) may
either inhibit or promote cancer progression [61], and the tumour
promoting subset is more prevalent in breast carcinomas; IBCs have
relatively high levels of TAMs [63]. Inﬂammatory cytokines have
also been reported to be released at high levels in IBC. As
mentioned earlier, for example, NFkB and related genes are often
upregulated in IBC and these genes play an important role in im-
munity, and also in the increased secretion of inﬂammatory cyto-
kines like IL6 or IL8 [63]. Cycloxygenase-2 (COX2) levels and/or
prostaglandin E2 (the main catalytic product of COX2) levels are
elevated in a range of tumours, including a subset of breast cancers.
Elevated COX2 levels are part of the molecular IBC signature
identiﬁed by theWorld IBC Consortium and are, therefore, also part
of the inﬂammatory changes associated with IBC. The role of
extrinsic factors in the tumour microenvironment, like TILs, TAMs
and cytokines may help to account for the differences in behaviour
between IBC and non-IBC, and other microenvironmental factors
provide an avenue for novel therapeutics.
Inducible nitric oxide synthase (NOS2) is an enzyme involved in
the production of nitric oxide (NO). It is upregulated in a high
proportion of ER-negative tumours with poor prognosis. Stimuli
like interferon-a or hypoxia result in overexpression of NOS2, and
NOS2 is downstream related to the release of inﬂammatory me-
diators linked to poor outcome in breast cancer (and also found to
be elevated in IBC), like IL6 or IL8. High levels of NOS2 and NO have
also been related to tumour growth and metastasis as well as
chemoresistance to paclitaxel [64]. Although NOS2 emerged as an
attractive biomarker of poor prognosis, and is linked to inﬂam-
mation, it has not been directly linked to IBC, and is not among the
IBC signature genes described by the World IBC Consortium [40].
Cancer stem cells
Cancer stem cells (CSCs) are a subpopulation of tumour cells
that exhibit speciﬁc features, which explain cellular heterogeneityDownloaded for Anonymous User (n/a) at HUNGARY - Szeged Uni
For personal use only. No other uses without permission.of tumours. They are responsible for a hierarchical organization of
tumour tissues where several subpopulations of self-renewing
breast CSCs sustain the long-term oligoclonality of the neoplasm
[65]. Moreover, these cells are responsible for recurrence and
metastasis [66] and they have been found to be mostly resistant to
conventional therapies compared with their non-tumorigenic
progeny [67].
IBC cells displayed a CSC subpopulation, which may contribute
to the aggressive andmotile characteristics of IBC [66]. In particular,
SUM-149 IBC cell line cells display CD44þ/CD24/low stem cell
surface markers, as well as aldehyde dehydrogenase-1, a maker of
CSC [66,68]. When CSCs with this phenotype were injected into
mice, they were highly tumorigenic [69]. The patient derived
xenograft model of IBC (MARY-X) exhibits this phenotype, along
with the unique stem cell marker CD133 [70]. Therapeutically,
targeting of this CSC phenotype within IBC cells via the Notch
pathway inhibition results in a signiﬁcant reduction in anchorage
independent growth of SUM-190 and SUM-149 IBC cell line cells
[71]. The sonic hedgehog pathway, a central pathway in stem cell
biology, is differentially regulated in IBC patients, and the down-
stream zinc-ﬁnger transcription factors of the glioma associated
oncogene (GLI) are the ﬁnal steps in the hedgehog pathway.
Modulation of GLI1 in IBC suggests it has a role in cell proliferation,
survival and migration, and this supports the feasibility of targeting
GLI1 as a potential therapeutic strategy for IBC patients [72].Concluding remarks
Despite the characteristic and distinguishing clinical presenta-
tion, IBC is not a homogeneous disease. Often it is of the type
associated with a poor prognostic proﬁle (no special type cancer of
high grade, belonging to the ER-negative subset and/or the HER2-
positive subset), examples with different histologic type, grade,
receptor status, intrinsic subtype are also represented in this
clinico-pathologic entity. There are several targetable changes in
IBC, some of which representmolecular pathways of carcinogenesis
while others represent pathways of inﬂammation and still others
are involved in different other biological processes. However, there
has been no unique characteristic identiﬁed for these tumours that
would allow a single therapeutic intervention. As IBC is a rare
manifestation of breast cancer, speciﬁc clinical trials are more
difﬁcult to be organized, and preclinical studies are important both
to advance our understanding of IBC pathophysiology and to select
which clinical trials should be favoured over others. As the
tumoural microenvironment is very important in IBC, and may be a
key to understand its clinical presentation and propose new ther-
apeutic modalities, models that include the tumour stroma [73]
might be of greater value than classical IBC cell lines in the study
of this entity. It has recently become possible to grow organoids
from breast cancer [74], that may be useful in this respect, espe-
cially when co-cultured with inﬂammatory cells or stromal cells, or
to use the new generation of humanized patient derived xenografts
with immune cells in mice.Conﬂict of interest statement
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